BEIJING, March 3 Tianyin Pharmaceutical Co.,Inc. (NYSE Alternext: TPI), a manufacturer and supplier of modernizedtraditional Chinese medicine ("TCM") based in Chengdu, China, today announcedit will present at the Rodman & Renshaw Annual China Investment Conferencebeing held March 7-9 in Beijing, China. Presentation details are noted below.
Conference participation is by invitation and registration is mandatory.For more information on the conference, or to book a one-on-one meeting,contact your Rodman & Renshaw representative or visit http://www.rodm.com .
About Rodman & Renshaw (NasdaqGM: RODM)
Rodman & Renshaw Capital Group, Inc., (NasdaqGM: RODM) offers corporatefinance services focusing on various public and private equity products, whichinclude private investment in public equity, registered direct offerings,private placements, and public offerings, as well as provides CollateralizedAcquisition Pool, a product used to facilitate a targeted acquisition. Thecompany also involves in strategic advisory services, which includeidentifying and/or evaluating acquisition targets or acquirers; providingvaluation analyses; evaluating and proposing financial and strategicalternatives; rendering fairness opinions; advising on timing, structure, andpricing of transaction; assisting in negotiating and closing a transaction;advising on the sale process; and assisting in preparing a memorandum or othersales materials. In addition, it provides merchant banking and assetmanagement services. Rodman & Renshaw Capital Group serves public and privatebiotechnology companies. The company is headquartered in New York, New York.
About Tianyin Pharmaceuticals
Tianyin is a manufacturer and supplier of modernized Traditional ChineseMedicine ("TCM") in China. It was established in 1994 and acquired by thecurrent management team in August 2003. Tianyin currently has 48 SFDA approvedproducts, 41 which are manufactured and marketed. 23 of these products arelisted in the highly selective National Medicine Catalog of the NationalMedical Insurance program. Tianyin owns and operates two GMP manufacturingfacilities and an R&D platform supported by leading Chinese academicinstitutions. The Company has also maintains a pipeline of 17 pharmaceuticalproducts pending approval. Tianyin has an extensive nationwide distributionnetwork throughout China with a sales force of 730 salespeople. The Company isheadquartered in Chengdu, Sichuan Province with two manufacturing facilitiesand a total of 1,365 employees. For more information about Tianyin, pleasevisit http://www.tianyinpharma.com .
Safe Harbor Statement
The Statements which are not historical facts contained in this pressrelease or upcoming conference presentation are forward-looking statementsthat involve certain risks and uncertainties including but not limited torisks associated with the uncertainty of future financial results, additionalfinancing requirements, development of new products, government approvalprocesses, the impact of competitive products or pricing, technologicalchanges, the effect of economic conditions and other uncertainties detailed inthe Company's filings with the Securities and Exchange Commission.Date: March 9, 2010 Time: 3:40 pm Beijing Time Location: Ballroom IIi, The Regent Hotel, Beijing China Presenter: Dr. Guoqing Jiang, Chairman and CEO Joined by: Mr. Allen Tang, Assistant to the CEO
SOURCE Tianyin Pharmaceutical Co., Inc.